| Serial Number | 87817929 |
| Word Mark | PREVANCIA |
| Filing Date | Friday, March 2, 2018 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, February 21, 2022 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 24, 2018 |
| Goods and Services | Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 9, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Allergan Sales, LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Irvine, CA 92612 |
| Party Name | Allergan Sales, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Madison, NJ 07940 |
| Event Date | Event Description |
| Tuesday, February 22, 2022 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, February 21, 2022 | ABANDONMENT - NO USE STATEMENT FILED |
| Wednesday, July 21, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, July 20, 2021 | EXTENSION 5 GRANTED |
| Monday, July 12, 2021 | EXTENSION 5 FILED |
| Monday, July 19, 2021 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Monday, July 12, 2021 | TEAS EXTENSION RECEIVED |
| Saturday, January 9, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, January 7, 2021 | EXTENSION 4 GRANTED |
| Thursday, January 7, 2021 | EXTENSION 4 FILED |
| Thursday, January 7, 2021 | TEAS EXTENSION RECEIVED |
| Tuesday, June 30, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, June 26, 2020 | EXTENSION 3 GRANTED |
| Friday, June 26, 2020 | EXTENSION 3 FILED |
| Friday, June 26, 2020 | TEAS EXTENSION RECEIVED |
| Saturday, January 11, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, January 9, 2020 | EXTENSION 2 GRANTED |
| Thursday, January 9, 2020 | EXTENSION 2 FILED |
| Thursday, January 9, 2020 | TEAS EXTENSION RECEIVED |
| Tuesday, June 18, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, June 14, 2019 | EXTENSION 1 GRANTED |
| Friday, June 14, 2019 | EXTENSION 1 FILED |
| Friday, June 14, 2019 | TEAS EXTENSION RECEIVED |
| Tuesday, January 15, 2019 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Sunday, December 2, 2018 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Wednesday, October 31, 2018 | CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED |
| Monday, October 22, 2018 | ASSIGNED TO PETITION STAFF |
| Tuesday, September 18, 2018 | TEAS POST PUBLICATION AMENDMENT RECEIVED |
| Wednesday, August 22, 2018 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, July 24, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 24, 2018 | PUBLISHED FOR OPPOSITION |
| Wednesday, July 4, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, June 14, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, June 14, 2018 | ASSIGNED TO EXAMINER |
| Friday, March 9, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, March 6, 2018 | NEW APPLICATION ENTERED IN TRAM |